Abstract
Introduction

9
Breast cancer is the most common malignant neoplasm with significant morbidity and of ILCs. We will refer to these cells henceforth as ILC3. ILC3 play a major role in lymphoid 20 tissue development both in the embryo (7) and in adult life (8, 9) . Within the secondary 21 lymphoid structures, ILC3 produce lymphotoxin (LT)α 1 β 2 which binds LTβR on respectively ( Figure 1G ). We then analysed the levels of CCL21 and CXCL13 present in 8 primary tumors and serum at various times after tumor establishment. CCL21 levels peaked 9 in both the tumor and serum at d12, before declining rapidly ( Figure 1H ). CXCL13 in the 10 tumor also peaked early (d10-12), but levels in serum lagged behind, peaking at d14. In 11 contrast to CCL21, CXCL13 oscillated, with tumor CXCL13 beginning to rise again at d20,
12
and serum CXCL13 concentration increasing at d24 ( Figure 1I ).
13
To examine the effect of CCL21 or CXCL13 blockade on NKp46 number of these cells had previously been shown to be present in the tumors ( Figure 1B ).
18
When compared with isotype controls, anti-CCL21, but not anti-CXCL13 neutralizing
19
antibodies, significantly reduced NKp46 -ILC3s recruitment to the primary tumor ( Figure 1J ). Figure S2) . production by interaction with MSC.
17
Next, we used an intravital mammary window (MIW) with multi-photon imaging to assess To strengthen the link between ILC and chemokines in LN metastasis we depleted ILCs with 5 anti-CD90.2, as previously described (25) ( Figure 3G ). It is noteworthy that anti-CD90. 2 6 does not specifically depletes ILC3 and is also able to deplete T cells. Therefore these 7 experiments were also carried out in Rag1 -/-mice. We found a significant decrease in the RANKL to 4T1.2 (between 10-100ng/ml) was observed to significantly increase the ability of 10 the tumour cells to invade through the matrix ( Figure 4F ).
11
To investigate the relationship between CXCL13 and RANKL expression in vivo, we 12 analysed the changes in the levels of RANKL in the sera of 4T1.2 tumor-bearing mice at a 13 number of timepoints after tumor establishment. RANKL levels peaked at d18 (P<0.0001, 14 unpaired t-test; Figure 4G ), approximately 4d after the first serum peak in CXCL13 ( Figure   15 1H). In mice treated with anti-CXCL13, levels of RANKL at d14 were significantly reduced 16 (P<0.001 unpaired t-test; Figure 4H ), in support of the idea that CXCL13 drives RANKL 17 production in vivo. A significant reduction in RANKL was also observed in anti-CCL21 18 treated mice (P<0.001 unpaired t-test; Figure 4H ).
19
These findings led us to hypothesise that RANKL, like CCL21 and CXCL13, might promote Consortium (METABRIC) (29) (see Supplementary Table S3 for patient characteristics).
10
Unsupervised hierarchical cluster analysis of the transcriptional profile in these samples T-cells and B-cells) and showed significant internal pair-wise correlation (P<10 4 , Figure 5B ).
20
We next stained frozen primary tumor sections for markers for RORγt case to case (range 0-56/mm 2 ) ( Figure 5D ) but patients with high tumor ILC3 counts were 6 also likely to have a high gene expression score for the ILC3-associated chemokines ( Figure   7 5D; P<0.001, Spearman correlation permutation test).
8
We next assessed the correlation of CXCL13 and CCL21 protein and gene expression levels 9 with ILC3 scores. Fifty-nine cases with known ILC3 scores were stained for CXCL13 or 10 CCL21 expression. For CXCL13 only stromal cells stained for this chemokine (Figure 5Ei ).
11
In contrast, CCL21 staining was positive for both tumoral and stromal cells. We quantified permutation-based Mann-Whitney; Figure 6B ). Given our in vitro and in vivo findings, we parameters (e.g. grade, tumor size, receptor status; Figure 6E ). Recent years have seen a growing appreciation of the pleiotropic nature of the TME (32). CCL21-dependent, whilst CXCL13 regulates their clustering with stromal cells (see Figure   16 7).
17
The CCL21/CCR7 axis plays a role in the progression of different malignancies (35, 36) .
18
These studies focus on the direct effects of CCL21 on CCR7-expressing tumor cells, rather 19 than on how CCL21 may modify the TME. We show that CCL21 is expressed both in 20 primary human breast cancers and in a mouse model of TNBC. In the mouse model, the peak 21 of CCL21 expression in tumors was closely followed by ILC3 recruitment, an association we
22
show to be causal through its prevention by CCL21 blockade, consistent with the melanoma 23 xenograft study correlating tumor expression of CCL21 and ILC3 cells recruitment (21).
24
CXCL13 was not required for ILC3 recruitment to tumors but was important for the 
